UWELL Biopharma   Report issue

For profit Phase 1
Founded: Taipei Taiwan (2004)

Organization Overview

First Clinical Trial
2017
NCT03811457
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

UWELL Biopharma

Active Ingredients

Drugs in Phase 1 Trials (1)

welgenaleucel (2 trials)

Drugs in Other Trials (1)

nkg2d car-t cell (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, B-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 3
  • # of Trial APIs: 2